Disc Medicine, Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemini Therapeutics, Inc. /DE (GMTX)
CIK: 0001816736
Period of Report: 2021-02-05

Reporting Person: Tananbaum James B. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-05	Common Stock	A	1500000	$10.00	Acquired	1500000	Indirect
2021-02-05	Common Stock	C	2928750	—	Acquired	2928750	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-05	Common Stock	$0	C	2928750	Disposed		Common Stock (2928750)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	441500	Indirect

Footnotes

F1: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021.

F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer.